- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
The 2022 revision of the Clinical Practice Guidelines for Pancreatic Cancer-general remarks-
-
- OKUSAKA Takuji
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
-
- NAKAMURA Masafumi
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
-
- YOSHIDA Masahiro
- Clinical Research Centers for Medicine, International University of Health and Welfare
-
- KITANO Masayuki
- Second Department of Internal Medicine, Wakayama Medical University
-
- ITO Yoshinori
- Department of Radiation Oncology, Showa University School of Medicine
-
- MIZUNO Nobumasa
- Department of Gastroenterology, Aichi Cancer Center Hospital
-
- HANADA Keiji
- Department of Gastroenterology, JA Onomichi General Hospital
-
- OZAKA Masato
- Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research
-
- MORIZANE Chigusa
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
-
- TAKEYAMA Yoshifumi
- Department of Surgery, Kindai University Faculty of Medicine
Bibliographic Information
- Other Title
-
- 総論
Search this article
Description
<p>The Clinical Practice Guidelines for Pancreatic Cancer were revised and re-published in July 2022, for the first time in 3 years. Revisions were incorporated according to the "Medical Information Network Distribution Service (Minds) Handbook for Clinical Practice Guideline Development 2020," which provides guidance for guideline development under direction of a new committee for revisions including 140 specialists. General remarks, introducing issues on which consensus is considered to have been reached, were placed in the first half of the revised guidelines. In the second half, important debatable clinical issues were carefully selected and 73 clinical questions and 112 statements with algorithms for diagnosis, treatment, chemotherapy and precision medicine for pancreatic cancer were provided. It is of particular significance in this revision that a group including 4 patient and public representatives and 4 health professionals was actively involved in both the development and implementation of the guidelines.</p>
Journal
-
- Suizo
-
Suizo 38 (2), 94-100, 2023-04-28
Japan Pancreas Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390577598081178368
-
- ISSN
- 18812805
- 09130071
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- OpenAIRE
-
- Abstract License Flag
- Disallowed